Shanghai, China

Jiangsong Lou

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Shanghai Pharmaceuticals Holding Co., Ltd.. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 15.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jiangsong Lou: Innovator in Pyrazolone-Fused Pyrimidine Compounds

Introduction

Jiangsong Lou is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of chemistry, particularly in the development of novel compounds with potential therapeutic applications. His work is characterized by a focus on innovative chemical structures that exhibit improved biological activity.

Latest Patents

Jiangsong Lou holds a patent for a pyrazolone-fused pyrimidine compound, which includes a preparation method and its applications. The patent discloses a compound represented by a specific formula that demonstrates enhanced inhibitory activity against WEE1 kinase. This advancement could have important implications in the development of new treatments.

Career Highlights

Lou is affiliated with Shanghai Pharmaceuticals Holding Co., Ltd., where he continues to engage in research and development. His work at this leading pharmaceutical company allows him to contribute to the advancement of medical science through innovative chemical solutions.

Collaborations

Some of his notable coworkers include Zhihui Zhang and Hui Ge, who collaborate with him on various research projects. Their combined expertise enhances the potential for groundbreaking discoveries in their field.

Conclusion

Jiangsong Lou's contributions to the field of chemistry, particularly through his patented pyrazolone-fused pyrimidine compound, highlight his role as an innovator. His work not only advances scientific knowledge but also holds promise for future medical applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…